Last updated: October 2, 2026
DURYSTA is a biodegradable implant containing bimatoprost that is placed in the anterior chamber of the eye. Current United States prescribing information indicates it for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Administration is limited to a single implant per eye without retreatment because of the risk of corneal endothelial cell loss and other corneal adverse reactions.
Fichte, Endl & Elmer Eyecare may discuss DURYSTA or another pressure-lowering treatment after reviewing the patient’s diagnosis, corneal health, angle anatomy, lens status, prior surgery, inflammation risk, medication history, target pressure, and treatment preferences. Current availability and the clinician providing the treatment should be confirmed during the consultation.
How DURYSTA Works
The implant releases bimatoprost over time and then biodegrades. Bimatoprost is a prostaglandin analog that lowers eye pressure by improving aqueous-fluid outflow. The implant does not restore vision already lost to glaucoma and does not guarantee that other pressure-lowering treatment will never be needed.
Who May Be Evaluated
Current labeling includes patients with open-angle glaucoma or ocular hypertension. Evaluation may include pressure measurements, optic-nerve and visual-field assessment, corneal endothelial health, angle examination, lens and capsule status, previous corneal surgery, active inflammation, and the patient’s history with topical medications.
Contraindications
Current prescribing information lists active or suspected ocular or periocular infection, corneal endothelial cell dystrophy such as Fuchs dystrophy, prior corneal transplantation or endothelial-cell transplant, an absent or ruptured posterior lens capsule, and hypersensitivity to bimatoprost or another product component among the contraindications.
Warnings and Limitations
DURYSTA has been associated with corneal adverse reactions and endothelial cell loss. It should be used cautiously in eyes with limited endothelial reserve, narrow angles, or anatomic obstruction. Macular edema, intraocular inflammation, and changes in pigmented tissues are also described in the prescribing information. The complete current label contains additional precautions and adverse reactions.
DURYSTA Compared With Other Options
Alternatives can include prescription eye drops, selective laser trabeculoplasty, another medication-delivery strategy, MIGS, or traditional glaucoma surgery. The decision depends on pressure goals, disease severity, corneal and angle findings, medication tolerance, adherence, prior treatment, and expected duration of benefit.
Compare glaucoma treatment categories.
Questions to Ask the Clinician
- Is DURYSTA appropriate for my glaucoma or ocular hypertension?
- What does my corneal endothelial examination show?
- Why is only one implant permitted in each eye?
- How will my pressure be monitored afterward?
- Could I still need drops, laser, or surgery?
- What symptoms require an urgent call?
Schedule a Glaucoma Evaluation
Call 1-800-309-2020 or request an appointment.
Prescribing and Patient Education Sources
This page provides general education and summarizes selected prescribing information. The complete current prescribing information and an individual examination control treatment decisions.
